Thrombosis Program and Anticoagulation Service
Our innovative approach
Children’s is known for our science-driven approach. In fact, we’re home to the world's most extensive pediatric hospital research enterprise; and we partner with elite health care and biotech organizations around the globe. Clinicians and researchers in the Thrombosis Program and Anticoagulation Service work to continuously improve and expand therapies for blood clots and clotting disorders.
- The Thrombosis Program and Anticoagulation Service has established monitoring and risk identification guidelines that are used throughout the hospital for those patients who require anticoagulation medications. These patients may receive anticoagulation therapy to treat a clot—or prevent it from even developing.
- Alan Michelson, MD, our program director, is the foremost expert in the field of platelets and platelet disorders. He is the editor of Platelets, the field’s premier academic text on these conditions.
Our program includes active research in thrombosis and anticoagulation. Children’s is home to the Center for Platelet Research Studies. The Center is an internationally recognized research group focused on the study of platelet function.
The center is an integrated research group that performs basic bench research, translational research, and clinical research on platelets and related aspects of hemostasis and thrombosis.
A particular research focus at the Center for Platelet Research Studies is antiplatelet therapy, including:
- novel molecules and mechanisms for therapeutic platelet inhibition
- the effects of antiplatelet agents on coagulation and inflammation
- the relationship between the degree of inhibition of platelet function and clinical outcomes (thrombosis vs. hemorrhage)
- the use of platelet function tests to guide antiplatelet therapy in order to obtain better clinical outcomes
For more information about the Center for Platelet Research Studies, contact Alan Michelson, MD, at 617-919-3036 or alan.michelson@childrens.harvard.edu.
